Literature DB >> 26504006

Breast Cancer Cell Lines Exhibit Differential Sensitivities to Microtubule-targeting Drugs Independent of Doubling Time.

April L Risinger1, Nicholas F Dybdal-Hargreaves1, Susan L Mooberry2.   

Abstract

BACKGROUND: Microtubule-targeting agents (MTAs) are a mainstay in breast cancer treatment, yet patient responses differ. The underlying mechanisms of these differences are unknown. While MTAs are mitotic inhibitors, recent evidence highlights that non-mitotic effects of these drugs can contribute to their anticancer effects. It is critical to identify the non-mitotic mechanisms that could contribute to differences among MTAs. However, it is not clear whether rapidly dividing cells in culture are optimal tools to address these mechanistic questions in interphase cells.
MATERIALS AND METHODS: Detailed concentration response curves for five MTAs in a panel of diverse breast cancer cell lines were generated.
RESULTS: Substantial differences among both drugs and cell lines, consistent with the clinical scenario, were observed. Importantly, these differences do not correlate with cell doubling time.
CONCLUSION: The interphase actions of MTAs are critical to the full spectrum of their effects in cancer cells, even in cell culture models. Copyright
© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  Microtubule; docetaxel; eribulin; ixabepilone; microtubule destabilizer; paclitaxel; vinorelbine

Mesh:

Substances:

Year:  2015        PMID: 26504006      PMCID: PMC4812601     

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  27 in total

1.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.

Authors:  Brian D Lehmann; Joshua A Bauer; Xi Chen; Melinda E Sanders; A Bapsi Chakravarthy; Yu Shyr; Jennifer A Pietenpol
Journal:  J Clin Invest       Date:  2011-07       Impact factor: 14.808

Review 2.  Microtubules as a target for anticancer drugs.

Authors:  Mary Ann Jordan; Leslie Wilson
Journal:  Nat Rev Cancer       Date:  2004-04       Impact factor: 60.716

Review 3.  Inhibitors targeting mitosis: tales of how great drugs against a promising target were brought down by a flawed rationale.

Authors:  Edina Komlodi-Pasztor; Dan L Sackett; Antonio Tito Fojo
Journal:  Clin Cancer Res       Date:  2012-01-01       Impact factor: 12.531

4.  Comparison of the activities of the truncated halichondrin B analog NSC 707389 (E7389) with those of the parent compound and a proposed binding site on tubulin.

Authors:  Donnette A Dabydeen; James C Burnett; Ruoli Bai; Pascal Verdier-Pinard; Sarah J H Hickford; George R Pettit; John W Blunt; Murray H G Munro; Rick Gussio; Ernest Hamel
Journal:  Mol Pharmacol       Date:  2006-08-29       Impact factor: 4.436

Review 5.  Mitosis is not a key target of microtubule agents in patient tumors.

Authors:  Edina Komlodi-Pasztor; Dan Sackett; Julia Wilkerson; Tito Fojo
Journal:  Nat Rev Clin Oncol       Date:  2011-02-01       Impact factor: 66.675

Review 6.  Recent progress with microtubule stabilizers: new compounds, binding modes and cellular activities.

Authors:  Cristina C Rohena; Susan L Mooberry
Journal:  Nat Prod Rep       Date:  2014-03       Impact factor: 13.423

7.  New colorimetric cytotoxicity assay for anticancer-drug screening.

Authors:  P Skehan; R Storeng; D Scudiero; A Monks; J McMahon; D Vistica; J T Warren; H Bokesch; S Kenney; M R Boyd
Journal:  J Natl Cancer Inst       Date:  1990-07-04       Impact factor: 13.506

8.  Influence of microtubule-associated proteins on the differential effects of paclitaxel and docetaxel.

Authors:  Y Fromes; P Gounon; R Veitia; M C Bissery; A Fellous
Journal:  J Protein Chem       Date:  1996-05

9.  In situ analysis of the action of Navelbine on various types of microtubules using immunofluorescence.

Authors:  S Binet; A Fellous; H Lataste; A Krikorian; J P Couzinier; V Meininger
Journal:  Semin Oncol       Date:  1989-04       Impact factor: 4.929

10.  In vivo cell-cycle profiling in xenograft tumors by quantitative intravital microscopy.

Authors:  Deepak R Chittajallu; Stefan Florian; Rainer H Kohler; Yoshiko Iwamoto; James D Orth; Ralph Weissleder; Gaudenz Danuser; Timothy J Mitchison
Journal:  Nat Methods       Date:  2015-04-13       Impact factor: 28.547

View more
  7 in total

1.  In Vivo Evaluation of (-)-Zampanolide Demonstrates Potent and Persistent Antitumor Efficacy When Targeted to the Tumor Site.

Authors:  Leila Takahashi-Ruiz; Joseph D Morris; Phillip Crews; Tyler A Johnson; April L Risinger
Journal:  Molecules       Date:  2022-07-01       Impact factor: 4.927

2.  Synthesis and Biological Evaluations of Electrophilic Steroids Inspired by the Taccalonolides.

Authors:  Nicholas A Clanton; Shayne D Hastings; Griffin B Foultz; Julie A Contreras; Samantha S Yee; Hadi D Arman; April L Risinger; Doug E Frantz
Journal:  ACS Med Chem Lett       Date:  2020-11-20       Impact factor: 4.632

3.  SIRT3, PP2A and TTP protein stability in the presence of TNF-α on vincristine-induced apoptosis of leukaemia cells.

Authors:  Liang-Jun Wang; Jing-Ting Chiou; Yuan-Chin Lee; Chia-Hui Huang; Yi-Jun Shi; Long-Sen Chang
Journal:  J Cell Mol Med       Date:  2020-01-13       Impact factor: 5.310

4.  Loss of G-Protein Pathway Suppressor 2 Promotes Tumor Growth Through Activation of AKT Signaling.

Authors:  Stefanie Chan; Emma Smith; Yuan Gao; Julian Kwan; Benjamin C Blum; Andrew M Tilston-Lunel; Isabella Turcinovic; Xaralabos Varelas; Maria Dafne Cardamone; Stefano Monti; Andrew Emili; Valentina Perissi
Journal:  Front Cell Dev Biol       Date:  2021-01-07

5.  Phenolic Fractions from Vaccinium vitis-idaea L. and Their Antioxidant and Anticancer Activities Assessment.

Authors:  Gabriele Vilkickyte; Lina Raudone; Vilma Petrikaite
Journal:  Antioxidants (Basel)       Date:  2020-12-11

6.  Cooperative antitumor activities of carnosic acid and Trastuzumab in ERBB2+ breast cancer cells.

Authors:  Carolina D'Alesio; Grazia Bellese; Maria Cristina Gagliani; Cinzia Aiello; Elena Grasselli; Gianluca Marcocci; Angela Bisio; Sara Tavella; Tiziana Daniele; Katia Cortese; Patrizio Castagnola
Journal:  J Exp Clin Cancer Res       Date:  2017-11-03

7.  FOXM1 repression increases mitotic death upon antimitotic chemotherapy through BMF upregulation.

Authors:  Sara Vaz; Fábio J Ferreira; Joana C Macedo; Gil Leor; Uri Ben-David; José Bessa; Elsa Logarinho
Journal:  Cell Death Dis       Date:  2021-05-25       Impact factor: 8.469

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.